CN102846679A - Composition with weight losing effect - Google Patents
Composition with weight losing effect Download PDFInfo
- Publication number
- CN102846679A CN102846679A CN2012102920911A CN201210292091A CN102846679A CN 102846679 A CN102846679 A CN 102846679A CN 2012102920911 A CN2012102920911 A CN 2012102920911A CN 201210292091 A CN201210292091 A CN 201210292091A CN 102846679 A CN102846679 A CN 102846679A
- Authority
- CN
- China
- Prior art keywords
- powder
- fat
- ginkgetin
- composition
- sodium cromoglicate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a composition with a weight losing effect. The composition is formed by uniformly mixing a mast cell membrane stabilizing agent, such as sodium cromoglycate powder, and ginkgetin powder extracted from ginko leaves in a mass ratio of 1:(1-100), wherein the content of sodium cromoglycate in the mast cell membrane stabilizing agent sodium cromoglycate powder is more than 98 percent; and the content of the ginketin in the ginkgetin powder is more than 50 percent. The composition can be mixed with the excipient of a make-up preparation or medicament to prepare an external preparation for skin, such as cream emulsion, gel, plaster, subcutaneous injection. Pharmacological testing proves that the composition has the effects of losing weight and reducing body fat and the number and volume of fat cells, and the functions of reducing blood sugar and blood fat. Trial results in fat crowd indicate that the composition has the functions of losing weight and eliminating fat, is safe to use and has no side effects.
Description
Technical field
The invention belongs to fat-reducing cosmetics and biomedicine field, be specifically related to cosmetics for external use or medicine for fat-reducing, namely the ginkgetin compositions of a kind of mastocyte membrane stabilizer sodium cromoglicate and natural origin has the function that reduces body weight and body fat.
Background technology
Fat incidence rate in China is 10%～20%.Developed country surpasses 60% crowd and is perplexed by obesity over past ten years.Obesity is not only brought apparent indecency to the people, also often have weak, breathe hard, the cardio palmus shape, not only affect quality of life of people, also can cause various diseases, human health in serious threat.Therefore, the control of obesity is caused people's attention day by day, one of the hot issue that become international of losing weight.
Fat essence is that the body fat acid metabolic is disorderly; And too much fat generation in the body, comprising the increase with volume of increasing of adipose cell quantity, lipocyte proliferation and disdifferentiation are fat pathologic basis.Method of weight-reducing is a lot of at present, and dietetic therapy, exercise therapy, pharmacotherapy etc. are arranged.Except adopting diet control, use effectively and little appetrol, slimming health food and the fat-reducing cosmetics of untoward reaction are important topics in the Medical research.But appetrol for oral administration, slimming health food easily cause side effect, such as diarrhoea, anorexia, hepatic injury etc.; And the external use to lose weight product directly acts on body fat accumulation place with the effective active composition of fat-reducing, directly promotes adipose cell to reduce or dwindles, and has easy to usely, has no side effect effect distinguishing feature, thereby extremely consumer's favor.But the most curative effects of the externally applied product of losing weight at present are dissatisfied.
In order to alleviate the misery of obese people physiology and psychology, market demand is developed a kind of mechanism of action uniqueness, curative effect is high and the novel dietetic composition external preparation of few side effects.Mastocyte membrane stabilizer sodium cromoglicate is the chemical drugs raw material, and the mechanism of performance antiobesity action is unique, has Adipocyte Differentiation and the effect ripe, that reduce adipose cell quantity and volume of suppressing; Ginkgetin is the material of natural origin, in blood fat reducing with improve and have obvious effect aspect the fatty acid metabolism, and both combinations, blending the east and the west, in the effect that can bring into play cooperative compensating aspect the antiobesity action mechanism.Therefore, developing this type of dietetic composition external preparation and have good prospect, is very useful and necessary to obese people.Have no the report that mastocyte membrane stabilizer and ginkgetin compatibility are used for the fat-reducing purposes.
Summary of the invention
The purpose of this invention is to provide a kind of compositions with antiobesity action, can make preparation for external application to skin with the mixed with excipients that is used for make-up preparation or medicine, it has the function that reduces body weight and body fat, has characteristics evident in efficacy, as to use safety.
The present invention is to mastocyte membrane stabilizer such as sodium cromoglicate powder, and Folium Ginkgo extracts and obtains ginkgetin powder, in mass ratio 1-1: 100 mix homogeneously obtain having the compositions of antiobesity action.Best mass ratio is 1: 10.Sodium cromoglicate content in mastocyte membrane stabilizer such as the sodium cromoglicate powder is greater than 98%; Flavonoid of ginkgo biloba in the ginkgetin powder is greater than 50%.Said composition can become preparation for external application to skin by known processes, such as cream frost emulsion, gel, pad pasting, subcutaneous injection agent etc.
Mastocyte membrane stabilizer sodium cromoglicate in the present invention's prescription, its raw material and preparation are recorded by multinational pharmacopeia such as China, the U.S., Britain.Sodium cromoglicate can be stablized mast cell membrane, sodium cromoglicate ointment and cream clinical practice in the treatment of skin allergy disease for many years, safe and effective.We smear with sodium cromoglicate ointment abdominal part and are applied to obese people, find to have the minimizing abdominal circumference, reduce the effect of body weight.Ginkgetin has effect for reducing blood fat, can improve lipid metabolism, promotes steatolysis, suppresses lipogenesis, and myocardial damage, hepatic injury and injury of kidney that hyperlipidemia is caused have protective effect.
The invention has the beneficial effects as follows that the pharmacology pharmacodynamic experimental study shows that external preparation of the present invention has the reduction body weight, reduce body fat, reduce adipose cell quantity and volume, and have the effect of blood sugar lowering and blood fat reducing.The local irritation test safety evaluatio studies show that safety of the present invention, without untoward reaction such as skin irritation, allergy, and application safety.The obese people result on trial shows that the present invention has the body weight of reduction and eliminates fatty function, uses safety to have no side effect.
The specific embodiment
Below in conjunction with embodiment, the present invention is done to describe further.
Embodiment 1:
A kind of compositions with antiobesity action is comprised of mastocyte membrane stabilizer sodium cromoglicate powder and the ginkgetin powder mix homogeneously that extracts from Folium Ginkgo, and 1: 10 mix homogeneously forms in mass ratio.
The sodium cromoglicate powder is for meeting " the sodium cromoglicate crude drug of two quality standards of Chinese pharmacopoeia, content 99.30%.
The ginkgetin extraction process is as follows: Folium Ginkgo is pulverized, extract with 70% alcohol heating reflux, merge extractive liquid,, Recycled ethanol also is concentrated into an amount of, be added on the AB-8 macroporous adsorbent resin of having handled well, the ethanol elution of water and variable concentrations is collected corresponding eluent successively, is condensed into extractum, vacuum drying, weigh, get the ginkgetin powder, and measure the content (mg/g) of ginkgetin.This product character is: the sundown powder, and odorless, mildly bitter flavor has hygroscopicity, is dissolved in alcohol, and is water insoluble.
Flavonoid of ginkgo biloba is measured: adopt the HPLC method to measure.Carry out qualitatively according to the retention time of standard specimen, calculate the content of ginkgetin with external standard method.This product flavonoid of ginkgo biloba is 511.82mg/g.
Ginkgetin extraction process and content assaying method are public method.
The preparation of cream prepares cream by public cream process of preparing.It is 20mg+200mg that every gram contains sodium cromoglicate+ginkgetin.
Embodiment 2:
A kind of compositions with antiobesity action is comprised of mastocyte membrane stabilizer sodium cromoglicate powder and the ginkgetin powder mix homogeneously that extracts from Folium Ginkgo, and 1: 1 mix homogeneously forms in mass ratio.
The preparation of cream prepares cream by public cream process of preparing.It is 100mg+100mg that every gram contains sodium cromoglicate+ginkgetin.
The other the same as in Example 1.
Embodiment 3:
A kind of compositions with antiobesity action is comprised of mastocyte membrane stabilizer sodium cromoglicate powder and the ginkgetin powder mix homogeneously that extracts from Folium Ginkgo, and 1: 50 mix homogeneously forms in mass ratio.
The preparation of cream prepares cream by public cream process of preparing.It is 5mg+250mg that every gram contains sodium cromoglicate+ginkgetin.
The other the same as in Example 1.
Embodiment 4:
A kind of compositions with antiobesity action is comprised of mastocyte membrane stabilizer sodium cromoglicate powder and the ginkgetin powder mix homogeneously that extracts from Folium Ginkgo, and 1: 100 mix homogeneously forms in mass ratio.
The preparation of cream prepares cream by public cream process of preparing.It is 2mg+200mg that every gram contains sodium cromoglicate+ginkgetin.
The other the same as in Example 1.
Embodiment 5:
A kind of compositions with antiobesity action is comprised of mastocyte membrane stabilizer sodium cromoglicate powder and the ginkgetin powder mix homogeneously that extracts from Folium Ginkgo, and 1: 10 mix homogeneously forms in mass ratio.
The preparation of emulsion agent prepares emulsion by public emulsion agent process of preparing.Every milliliter contains sodium cromoglicate+ginkgetin is 20mg+200mg.
The other the same as in Example 1.
Embodiment 6:
A kind of compositions with antiobesity action is comprised of mastocyte membrane stabilizer sodium cromoglicate powder and the ginkgetin powder mix homogeneously that extracts from Folium Ginkgo, and 1: 50 mix homogeneously forms in mass ratio.
The preparation of emulsion agent prepares emulsion by public emulsion agent process of preparing.Every milliliter contains sodium cromoglicate+ginkgetin is 5mg+250mg.
The other the same as in Example 1.
Embodiment 7:
A kind of compositions with antiobesity action is comprised of mastocyte membrane stabilizer sodium cromoglicate powder and the ginkgetin powder mix homogeneously that extracts from Folium Ginkgo, and 1: 10 mix homogeneously forms in mass ratio.
The preparation of gel prepares gel by public gel process of preparing.It is 20mg+200mg that every gram contains sodium cromoglicate+ginkgetin.
The other the same as in Example 1.
Embodiment 8:
A kind of compositions with antiobesity action is comprised of mastocyte membrane stabilizer sodium cromoglicate powder and the ginkgetin powder mix homogeneously that extracts from Folium Ginkgo, and 1: 100 mix homogeneously forms in mass ratio.
The preparation of gel prepares gel by public gel process of preparing.It is 2mg+200mg that every gram contains sodium cromoglicate+ginkgetin.
The other the same as in Example 1.
Embodiment 9:
A kind of compositions with antiobesity action is comprised of mastocyte membrane stabilizer sodium cromoglicate powder and the ginkgetin powder mix homogeneously that extracts from Folium Ginkgo, and 1: 10 mix homogeneously forms in mass ratio.
The preparation of membranous patch prepares pad pasting by public membranous patch process of preparing.Every contains sodium cromoglicate+ginkgetin is 20mg+200mg.
The other the same as in Example 1.
Embodiment 10:
A kind of compositions with antiobesity action is comprised of mastocyte membrane stabilizer sodium cromoglicate powder and the ginkgetin powder mix homogeneously that extracts from Folium Ginkgo, and 1: 10 mix homogeneously forms in mass ratio.
The preparation of subcutaneous injection agent prepares the subcutaneous injection agent by public subcutaneous injection agent process of preparing.Every milliliter contains sodium cromoglicate+ginkgetin is 20mg+200mg.
The other the same as in Example 1.
In order to the external preparation that the top method is made, the pharmacology pharmacodynamic test of being correlated with, the experiment of local irritation safety evaluatio and clinic trial test.The below is experimental data of the present invention:
The foundation of mice alimentary obesity model is with reference to the relevant experimental technique of Ministry of Public Health " health food check and assessment technique standard ", with high fat diet inducing obesity mice.Mice is divided into Normal group and obese model group at random by body weight, gives respectively normal diet and high lipid food, does not limit diet, continues for 8 weeks.High lipid food is mixed and processed by 50% normal feedstuff, 15% flour, 12% Adeps Sus domestica, 3% yolk powder, 4% analysis for soybean powder, 2% Sal, 12% sucrose, 2% whole milk powder.After the modeling, to exceed Normal group average weight 20% as obesity standard, screen standard compliant obesity mice.
After 8 all obesity mice modelings success is induced in high fat diet, 40 of obesity mices are divided into 2 groups at random by body weight: model control group and of the present invention group, 20 every group; Experimental session model contrast and of the present invention group give high fat diet.Other gets 20 normal mouses as Normal group, gives full diet.Of the present invention group of mouse web portion is coated with slimming cream of the present invention outward, and obese model and Normal group mouse web portion are coated with substrate outward, every day 1 time, continuous 4 weeks.During this period, each organizes mouse web portion depilation in per 3 days once.Claim respectively to organize weekly Mouse Weight.Fasting 12h before experiment finishes claims final body weight, and then separation of serum detects blood fat: triglyceride (TG), T-CHOL (TC) and free fatty (FFA) content and blood sugar level.Get the stomach fat pad, weigh after filter paper blots.Get stomach fat, fix with 10% formalin solution, the routine paraffin wax embedding, section, HE dyeing is observed adipose cell under Powerful Light Microscope, and the size with micrometer measurement adipose cell represents with cell (major diameter+wide footpath)/2.
Experimental result shows, compares with Normal group, and the obesity mice body weight significantly raises, and stomach fat weight obviously raises, and microscopically is observed adipose cell and obviously increased.Weight reducing compound of the present invention can reduce obesity mice body weight and stomach fat weight, and can make the stomach fat cell volume dwindle (seeing Table 1, table 2).Illustrate that the present invention has the effect of obvious fat-reducing and reduction body fat.The present invention also can reduce blood glucose and the blood lipid level (seeing Table 2, table 3) of obesity mice, illustrates that Weight reducing compound of the present invention can absorb to enter in the body performance blood sugar lowering and effect for reducing blood fat.
Table 1. is on the impact of the obesity mice body weight of absorption high fat diet
X ± s.n=20. compares with model group, * * P＜0.01.
Table 2. is on the impact (experimental program 1) of obesity mice body fat, adipose cell size and the blood glucose of absorption high fat diet
X ± s.n=20. compares with model group, * * P＜0.01.
Table 3. is on the impact (experimental program 1) of the obesity mice blood lipid level of absorption high fat diet
X ± s.n=20. compares with model group, * * P＜0.01.
More than in the experiment, each mice general state is good, and it is normal to ingest, drink water, and the mental status is good, without the diarrhoea phenomenon.Skin of abdomen is all normal, without the uncomfortable reaction such as allergy, redness, desquamation.Product safety of the present invention is described, almost non-toxic side reaction.
Local irritation test: get 8 of adult rabbit, male and female half and half, every animal sub-cage rearing was raised 3-4 days at laboratory condition first.Then rabbit spinal column both sides dorsal body setae is shaved off every lateral area 5 * 10cm with electric shaver-for women
2Check that carefully whether the depilation district has redness and damage, if any abandoning it, can not test.Adopt the test method of multiple dosing, dietetic composition cream of the present invention is smeared in the district in depilation, every day 2 times, gives continuously 7 days.Whether last gives after 24 hours to observe the local skin reaction with warm water flush away smear after 1,24,48,72 hour, such as erythema, edema, desquamation, incrustation etc., have petechia, skin peptide coarse or poor etc., record time of origin and regression time.The result shows, is smearing continuously the present invention after 7 days, and each rabbit skin does not all show obvious skin irritation and anaphylaxis.Show product safety of the present invention, have no adverse reaction.
Clinic trial test: on probation through 100 routine obese peoples in order to the slimming cream that the top method is made, male 50 examples wherein, women 50 examples, 37 years old mean age.Diet products of the present invention are applied to the fattiness position of abdominal part equably, every night once, and clockwise massage, about 3-5 minute at every turn.1 month is a course for the treatment of.During treating, all do not use any other diet products, and normal diet.Observation index is abdominal circumference and body weight.Index of assessment of curative effect: lose weight 3 kilograms, it is produce effects more than 3 centimeters that abdominal circumference reduces; Lose weight below 3 kilograms, more than 1 kilogram or abdominal circumference reduce below 3 centimeters, be effective more than 1 centimeter; Body weight and abdominal circumference fluctuate in 0.5 kilogram or 0.5 centimeter person as invalid.Clinical observation result sees Table 4.The result shows, uses the effect that dietetic composition cream of the present invention has obvious minimizing abdominal circumference to obese people and reduces body weight.All triers the untoward reaction such as skin irritation, allergy all do not occur during using the present invention.Therefore the present invention is a kind of comparatively ideal fat-reducing external preparation, and is safe and reliable.
The clinical application effect of table 4 dietetic composition cream of the present invention
Claims (3)
1. compositions with antiobesity action is characterized in that: by mastocyte membrane stabilizer such as sodium cromoglicate powder, and by the ginkgetin powder that from Folium Ginkgo, extracts in mass ratio 1: the 1-100 mix homogeneously forms;
Sodium cromoglicate content in the described mastocyte membrane stabilizer sodium cromoglicate powder is greater than 98%;
Flavonoid of ginkgo biloba in the described ginkgetin powder is greater than 50%.
2. a kind of compositions with antiobesity action according to claim 1 is characterized in that: described mastocyte membrane stabilizer such as sodium cromoglicate powder, and the ginkgetin powder that from Folium Ginkgo, extracts in mass ratio 1: 10 mix homogeneously form.
3. a kind of compositions with antiobesity action according to claim 1 can be made preparation for external application to skin with the mixed with excipients of make-up preparation or medicine, such as cream frost emulsion, gel, pad pasting, subcutaneous injection agent etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102920911A CN102846679A (en) | 2012-08-14 | 2012-08-14 | Composition with weight losing effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102920911A CN102846679A (en) | 2012-08-14 | 2012-08-14 | Composition with weight losing effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102846679A true CN102846679A (en) | 2013-01-02 |
Family
ID=47393924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102920911A Pending CN102846679A (en) | 2012-08-14 | 2012-08-14 | Composition with weight losing effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102846679A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432192A (en) * | 2013-09-15 | 2013-12-11 | 王青 | Composition with slimming function |
| CN109045015A (en) * | 2018-07-26 | 2018-12-21 | 大连天星本草生物科技有限公司 | A kind of ginkegetin class compound is preparing the application in slimming medicine and/or pharmaceutical composition for slimming |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1335142A (en) * | 2000-07-26 | 2002-02-13 | 雷学军 | Weight reducing water containing natural medicinal component and its prepn |
| CN101808642A (en) * | 2007-09-28 | 2010-08-18 | 布里格海姆妇女医院公司 | Mast cell stabilizers in the treatment of obesity |
| CN102204871A (en) * | 2011-06-01 | 2011-10-05 | 王青 | Composition for weight loss |
| CN102397304A (en) * | 2007-08-07 | 2012-04-04 | 北京北大维信生物科技有限公司 | Application of Chinese herbal medicine ginkgo biloba extract to preparation of medicament for reducing weight and lipid or preparation of medicament with lipase activity inhibitory action |
-
2012
- 2012-08-14 CN CN2012102920911A patent/CN102846679A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1335142A (en) * | 2000-07-26 | 2002-02-13 | 雷学军 | Weight reducing water containing natural medicinal component and its prepn |
| CN102397304A (en) * | 2007-08-07 | 2012-04-04 | 北京北大维信生物科技有限公司 | Application of Chinese herbal medicine ginkgo biloba extract to preparation of medicament for reducing weight and lipid or preparation of medicament with lipase activity inhibitory action |
| CN101808642A (en) * | 2007-09-28 | 2010-08-18 | 布里格海姆妇女医院公司 | Mast cell stabilizers in the treatment of obesity |
| CN102204871A (en) * | 2011-06-01 | 2011-10-05 | 王青 | Composition for weight loss |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432192A (en) * | 2013-09-15 | 2013-12-11 | 王青 | Composition with slimming function |
| CN103432192B (en) * | 2013-09-15 | 2015-08-19 | 王青 | A kind of compositions with antiobesity action |
| CN109045015A (en) * | 2018-07-26 | 2018-12-21 | 大连天星本草生物科技有限公司 | A kind of ginkegetin class compound is preparing the application in slimming medicine and/or pharmaceutical composition for slimming |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103432192B (en) | A kind of compositions with antiobesity action | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN101607051A (en) | A kind of Chinese medicine Weight reducing compound and preparation method thereof | |
| CN107912773A (en) | A kind of preparation for being used to alleviate physical fatigue | |
| CN102846679A (en) | Composition with weight losing effect | |
| CN1939427B (en) | Prickly polygonum extract, its preparation, medicinal composition and use | |
| CN101474346B (en) | Longstamen onion bulb extract as well as preparation method and application thereof | |
| CN102641338A (en) | Massage medicament for treating soft tissue injury | |
| CN102204871A (en) | Composition for weight loss | |
| CN103830374A (en) | Application of three-leaf glycolipid-removal medicine in hyperuricemia | |
| KR101511364B1 (en) | Herbal Extract Composition for Prevention or Treatment of Obesity and Metabolic Syndrome Using Herbal Extract | |
| CN101143203B (en) | Compound oral liquid with liver-protecting and stomach-nourishing function | |
| CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN102526672A (en) | Traditional Chinese medicine composition, applications and preparation method | |
| CN1927309B (en) | Traditional Chinese medicine composition detection method | |
| CN102579947B (en) | Chinese medicinal composition and preparation method thereof | |
| CN102793767B (en) | Radix notoginseng pharmaceutical composition for treating insomnia as well as preparation method and application of pharmaceutical composition | |
| CN111480846A (en) | Health-care product for assisting in reducing blood fat and improving immunity | |
| CN106138215A (en) | A kind of medicine for treating eczema | |
| CN102846678A (en) | Application of ginkgolic acid in weight losing | |
| CN104906194B (en) | A kind of medicinal plaster treating asthma and preparation technology and determination method | |
| CN108403759A (en) | A kind of health composition and its preparation method and application | |
| CN101698096B (en) | Plaster for treating white vein diseases and preparation method thereof | |
| CN104940478A (en) | Ginseng antler brain-nourishing prescription for treating AD diseases | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130102 |